[1]
T. Oscanoa, S. Moscol, and J. Amado, “Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru”, Rev Peru Med Exp Salud Publica, vol. 37, no. 3, pp. 516–20, Sep. 2020, doi: 10.17843/rpmesp.2020.373.4684.